Introduction
Psoriatic arthritis (PsA) is a systemic inflammatory joint disease with a heterogeneous clinical presentation that may include peripheral or axial arthritis with altered bone phenotypes, enthesitis, dactylitis, and plaque psoriasis. Psoriasis is a relatively common disease, affecting about 2 % of the general population; up to 25 % of these patients develop PsA about 10 years after the development of skin disease [1] . Increasing knowledge about the pathophysiology of psoriasis and PsA has revealed that the diverse disease manifestations observed in these disorders may share common immunologic and inflammatory pathways. In the case of psoriasis, antigen driven activation of dendritic cells by interferon α (IFN-α) promotes a Th1 and Th17 cell response in lymph nodes draining the skin [2, 3] . These cell subpopulations release a variety of cytokines including interleukin (IL) 17, IL21, IL22, and IL23 and tumor necrosis factor α (TNF-α), which trigger inflammatory cascades in several cell lineages resulting in altered tissue phenotypes, presenting clinically as psoriatic plaques and, as mentioned, about a quarter develop musculoskeletal problems including synovitis, dactylitis, enthesitis, and axial disease [4] [5] [6] .
Ustekinumab (UST), a monoclonal antibody that targets the shared p40 subunit of IL12 and IL23, was demonstrated to be highly efficacious and safe in psoriasis. Based on these encouraging results, a phase II study was performed in PsA, followed by two phase III clinical trials, which included both anti-TNF naïve and experienced patients [7•, 8•] . Herein, we will review the pathophysiology of the different manifestations of PsA, present data on the efficacy and safety of UST in PsA, and conclude with a discussion of pipeline agents that target different molecules in the IL23/Th17 pathway.
About IL12 and IL23
The IL12 family of cytokines consists of IL12, IL23, IL27, and IL35, all of which are heterodimers. IL12 is comprised of p40 and p35 subunits, while IL23 consists of p40 and p19 [9] . All cytokines in this family are secreted by activated antigen-presenting cells (dendritic cells specifically) and are involved in interferon-mediated differentiation of naïve T cells.
IL12 receptors consist of two components IL12Rβ1 and IL12Rβ2. The IL12Rβ2 becomes phosphorylated and provides a binding site for two kinases: Tyrosine kinase 2 (TYK2) and Janus kinase 2 (JAK2). These activated motifs modulate signal transduction through the STAT4 and STAT6 pathways, which then initiate transcription of interferon γ (IFN-γ) and IFN-α. Therefore, IL12 ultimately triggers Th1 differentiation and activation of natural killer (NK) cells [9] .
The IL23 receptor consists of the IL12Rβ1 and IL23R components. The p40 subunit of IL23 binds to the IL12Rβ1 receptor, and the p19 subunit of the cytokine binds to the IL23R component. Binding of this cytokine to its receptor leads to activation of STAT3, which upregulates the expression of retinoic acid receptor-related orphan receptor gamma (ROR-γ) transcription factor, which in turn promotes differentiation of naïve T cells to a Th17 phenotype characterized by the ability to release IL17, IL21, IL22, and TNF-α. IL17 supports survival and expansion of Th17 cells (Fig. 1a) [9] . Thus, inhibition of IL12, IL23, and IL17 blocks the differentiation of naïve T cells into Th1 and Th17 lymphocytes.
IL23 and psoriatic arthritis
The central importance of the IL23/Th17 pathway in human disease was initially identified in psoriasis. Injury to the skin by either trauma or infection causes cell death and the release of the antimicrobial cathelicidin LL37 by keratinocytes, which binds intracellular toll-like receptors (TLRs), resulting in the activation of plasmacytoid dendritic cells [3] . These dendritic cells release IFN-α, which activates the dermal myeloid dendritic cells and promotes their migration to the lymph nodes [10] . In the lymph node, myeloid dendritic cells secrete IL12 and IL23, which induce differentiation of the naïve T cells into Th1 and Th17 cells, respectively [2, 6, 11, 12] . These effector cells then exit the lymph node and re-enter circulation and return to the dermis, a chemotactic process facilitated by expression of surface chemokine receptors CCR4, CCR6, CCR7, and CXCR3 and homing molecules CLA, VLA-4, and LFA-1 [13] . In the skin, Th17 cells secrete cytokines including IL17, IL21, and IL22; the latter found to lead to proliferation of keratinocytes [14] . Likewise, intradermal injection of IL21 has been shown to stimulate human keratinocytes to proliferate and causes epidermal hyperplasia in murine models [15] . This pathologic hyperproliferation of keratinocytes leads to the characteristic thickening of the epidermis observed in psoriasis [14, 16] . Initial clues to the involvement of the IL23/IL17 axis in spondyloarthritis (SpA) arose from the observation that a polymorphism in the receptor for IL23 (IL-23R) was associated with altered susceptibility to ankylosing spondylitis and PsA [17, 18] . Specifically, R381Q IL23R carriers show decreased IL23-dependent IL17 and IL22 production and a lower percentage of circulating Th17 cells [19] . These individuals also showed a decreased IL23-dependent signaling. Interestingly, IL23R R381Q gene carriers are protected against psoriasis, Crohn's disease, and ankylosing spondylitis [20] .
Later studies showed that patients with SpA have elevated IL12 and IL23 levels in their synovial fluid and peripheral blood [21] . Elevated IL23 levels have been linked to the presence of human leukocyte antigen B27 (HLA-B27) positivity among these patients [22] . Moreover, in vitro and pre-clinical studies have shown that misfolding in the HLA-B27 protein leads to release of IL23 [22, 23] . IL23, in turn, induces the proliferation of Th17 cells, which then release pro-inflammatory cytokines [24] .
The IL23/Th17 axis has been implicated in many of the features that characterize PsA. For example, enthesitis or inflammation at the tendon, ligament, and joint capsule insertion sites is a cardinal feature of PsA. In a recent study, Sherlock et al. [4] showed that administration of IL23 to mice lead to the proliferation of a resident population of innate IL23R+ CD3+ CD4− CD8− T cells at the tendon insertion sites. In turn, enthesitis was associated with increased levels of IL6, IL17, and IL22, which was not observed when mice were pre-treated with anti-IL23 antibody. They concluded that IL23 alone, in the absence of any other inflammatory signal, was sufficient to reproduce the classical enthesitis feature of PsA. The presence of entheseal resident T cells, which expresses the RORγt transcription factor and secrete an array of TH17-associated cytokines, including IL22, may explain how dysregulation of IL23 results in inflammation and new bone formation at the entheses in the absence of synovitis [4, 18] .
Another key signal transduction molecule in the T cell development is ZAP-70. Mice with an activating mutation in the SH2 domain of this molecule develop axial and peripheral arthritis, which is suppressed in the absence of IL17. Furthermore, studies in SKG mice (ZAP-70 knockout model) have demonstrated that the development of the joint, bone, entheseal, and dactylitic inflammation in these mice is IL23 mediated [25] . Thus, emerging data in animal models implicate an important role for the IL17/IL23 axis in the pathophysiology of psoriasis, enthesitis, synovitis, and abnormal bone turnover in PsA.
Challenges in the treatment of psoriatic arthritis
The treatment of PsA has been challenging owing to a lack of high-quality trial data supporting the efficacy and safety of traditional disease-modifying antirheumatic drugs (DMARDs). In particular, studies analyzing the efficacy of oral DMARDs have shown no improvement over placebo in the case of methotrexate [26, 27] and small effect sizes for sulfasalazine [28] . One phase IIb study did reveal efficacy for leflunomide for the joints only, but a phase III study was never performed [29] . Likewise, a large, retrospective US database looked at patients treated with DMARDs (n=1698) vs. biologics (n=3263) over a 4-year period found that 69 % of patients in the DMARD group required a change in therapy. Of these patients, 64 % were switched to a biologic, and 25 % had a therapy add on. Among the patients who were started on a biologic initially 46 % required a therapy change, and of these, 25 % were switched to a different biologic with 7 % having a therapy add on [30•] .
Anti-TNF agents have rapidly moved to the center of the treatment paradigm in PsA due to their efficacy for both skin and musculoskeletal involvement based on high-grade evidence from placebo-controlled trials [31] . Despite the enthusiasm for these agents, the long-term efficacy data are not that encouraging. Up to 40-50 % of patients fail to reach the ACR20 outcome measures in most trials due to primary or secondary non-response or are unable to tolerate these agents [32•] . Moreover, the NOR-DMARD Registry, a multicenter observational study in Norway, looked at 439 patients with PsA who were on their first anti-TNF and reported that if a patient had failed to tolerate or respond to an anti-TNF agent, they had a 60-80 % chance of remaining unresponsive after switching to a second anti-TNF agent [32•] . Therefore, these studies highlight the high rate of change in therapies in PsA patients and underscore the need for additional treatment options.
Ustekinumab
Ustekinumab is a humanized IgG monoclonal antibody that binds to the P40 subunit common to IL12 and IL23 (Fig. 1b) . In the initial in vitro studies, human peripheral blood mononuclear cells (PBMCs) from healthy donors were activated in the presence or absence of recombinant human IL12 or IL23, with or without UST. In the presence of UST, the cell cultures showed reduction in the level of the skin homing molecule CLA as well as reduction in the secretion of IFN-α, TNF-α, IL17, and IL22 secretion. Therefore, it was concluded that UST would both neutralize the IL12/23 pathway and decrease expression of skin homing and activation markers [33] . In another study, x-ray crystallography demonstrated that UST binds with nearly equal affinity to the p40 component of both IL12 and IL23 [34] .
Ustekinumab in psoriasis
The initial utility of UST was studied in psoriasis, starting with pre-clinical studies and followed by six clinical trials that showed UST to be an effective and relatively safe treatment for psoriasis [35] . PHOENIX 1 and PHOENIX 2 were two pivotal phase III trials that examined the efficacy and safety of UST in psoriasis. These clinical trials were designed to assess long-term efficacy and safety of UST compared with placebo. PHOENIX 1 was a parallel double-blind placebo-control (DBPC) study of 766 patients with moderate-to-severe psoriasis. The subjects were randomly assigned to receive 45 or 90 mg of UST at weeks 0, 4, and then every 12 weeks. The control group received placebo at 0 and 4 weeks and were crossed over to receive UST at 12 weeks. At 12 weeks, 67.1 % of patients who received 45 mg, 66.4 % of patients who received 90 mg, and 3.1 % of those receiving placebo achieved PASI75. They also found that PASI75 response was better maintained at least 1 year in those who were continued on UST vs. those who were withdrawn.
Rates of adverse events were generally comparable between subjects in the placebo, UST 45 mg, and UST 90 mg groups [36] .
PHOENIX 2 was a large multicenter, DBPC study of 1230 patients with moderate-to-severe psoriasis who were again assigned to placebo vs. 45 or 90 mg of UST at weeks 0, 4, and then every 12 weeks. The primary endpoint was measured at 12 weeks; 66.7 % of patients receiving 45 mg of UST and 75.6 % of those receiving 90 mg of UST had achieved PASI75, compared with 3.7 % of patients in the placebo group. Therefore, the PHOENIX 2 trial suggested that dosing intensification would improve clinical response rate in patients with incomplete response to initial treatment with UST [37] .
Overall, the PHOENIX trials demonstrated impressive long-term efficacy. The ACCEPT trial was another phase III trial, which was a head-to-head comparison of UST with etanercept (an anti-TNF monoclonal antibody) in 903 patients with moderate-to-severe psoriasis, which showed superiority of UST at 12 weeks [38] . These phase II and III studies involved predominantly Caucasian patients. The PEARL trail was a randomized DBPC trial of 121 Taiwanese and Korean patients with moderate-to-severe psoriasis randomized with a treatment with 45 mg of UST vs. placebo. The results showed that the efficacy (and safety) rates in Asian patients were consistent with previous studies [39] . In 2009, the Food and Drug Administration approved its use for adult patients with moderate-to-severe plaque psoriasis in the US, and approval for this indication in Canada and Europe followed shortly thereafter.
Efficacy of ustekinumab in psoriatic arthritis
Gottlieb et al. published a phase II randomized DBPC and cross over study of UST in 2009. They studied 146 patients with active PsA, with greater than three tender and swollen joints and either an elevated C-reactive protein (CRP) or significant morning stiffness (945 min). Patients were also required to have at least one active psoriatic plaque measuring a minimum of 2 cm in diameter. About 25 % of the subjects had previously been treated with an anti-TNF agent for PsA. Subjects in the UST arm received 63 mg of the drug at weeks 0, 1, 2, and 3 followed by placebo at weeks 12 and 16. The subjects in the control group received placebo for the first four doses and UST at weeks 12 and 16. The primary endpoint was the percentage of patients who achieved an American College of Rheumatology (ACR) 20 improvement at 12 weeks. They found that 42 % of the patients in the active group achieved an ACR20 at 12 weeks, compared with only 14 % of patients in the control group (Table 1) . At 36 week follow-up, having received two doses of UST, 45 % of patients in the control group achieved ACR20 [40] . Patients in this study also demonstrated a statistically significant improvement in their quality of life as measured by a 59 % improvement in the measured Dermatology Life Quality Index (DLQI) [41] .
Based on the efficacy in the phase IIb trial, two multicenter DBRPC trials of UST in PsA known as PSUMMIT 1 and PSUMMIT 2 were initiated. PSUMMIT 1 recruited 615 patients naïve to anti-TNF therapy. Patients on DMARDs or NSAI D therapy were included in the study. All subjects selected met the Classification Criteria for Psoriatic Arthritis (CASPAR) Criteria for PsA and had active disease based on presence of at least five swollen joints and at least five tender joints. They were randomized 1:1:1 to receive UST of 45 mg, 90 mg, or placebo at 0, 4, and 12 weeks. In this study, nearly 50 % of patients were on concomitant methotrexate. Patients were eligible for early escape at week 16 if they demonstrated G5 % improvement in total or swollen joint and the dose of UST was increased (placebo to 45 mg UST and 45 to 90 mg of UST, 90 mg UST continued this dose). Any patients who remained in the placebo group at week 24 crossed over to receive 45 mg of UST, which was continued at week 28 and then every 12 weeks. Subjects were followed for 52 weeks total [7•, 8•, 42, 43] .
The primary endpoint was ACR20 response at 24 weeks, but the authors also examined ACR 50/70, Disease Activity Score (DAS) 28 using CRP (DAS28-CRP) PASI 75 response Health Assessment Questionnaire-Disability Index (HAQ-DI), and percentage of change in enthesitis and dactylitis scores as secondary measures. Both UST 45 and 90 mg showed a statistically significant improvement in ACR20 response compared to placebo at 24 weeks, and this response difference was maintained at 52 weeks. Likewise, compared with placebo, treatment with either dose of UST resulted in a significantly higher proportion of patients with DAS28-CRP scores less than 2.6 at week 24. Of the patients who had dactylitis at baseline, patients on UST had significantly greater improvement in their dactylitis and enthesitis scores at 24 weeks, compared with placebo. Moreover, the HAQ-DI change from baseline was −0.3 in both treatment groups, compared with 0 in the placebo group. No unexpected adverse reactions were observed in this study. Therefore, PSUMMIT 1 demonstrated that IL12/23 blockade significantly improved active PsA compared with placebo [7•, 8•, 43] .
One of the difficulties with the utility of the results from the PSUMMIT 1 trial was that it only included anti-TNF naïve subjects and in clinical practice, most patients have previously been treated with an anti-TNF agent at some point in their disease history. Therefore, there was a need for a viable treatment option for PsA patients who were inadequate responders or did not tolerate anti-TNF agents. PSUMMIT 2 was a second phase III multicenter DBRPC trial, which aimed to address this necessity.
PSUMMIT 2 enrolled 312 adults with PSA who had at least five tender and five swollen joints and a CRP level greater than 0.3 mg/dL. Of these patients, 180 had previous exposure to anti-TNF treatments, and the remaining 132 were anti-TNF naïve. The study design was otherwise identical to PSUMMIT 1, including blinded early escape for patients who failed to show improvement at 16 weeks. The primary endpoint was ACR20 response at week 24. Secondary endpoints included ACR50/70 response, DAS28-CRP response, PASI75, improvements in enthesitis and dactylitis scores, and improvements in HAQ-DI scores. Forty four percent of patients in the UST 45 and 90 mg achieved ACR20, compared with 20 % of patients in the placebo group. Looking at the secondary endpoints, the patients in both active groups had a statistically significant improvement in DAS28-CRP, PASI 75, and ACR50, with the benefits sustaining at 52 weeks. Interestingly, patients who were anti-TNF naïve responded better to UST than patients who had been previously exposed ( Table 1 ). The authors proposed that while the exact cause for this is not clear, it is conceivable that exposure to biologics alter the natural history of the disease. Therefore, PSUMMIT 2 established the efficacy of UST in a more clinically relevant context and showed no significant adverse events [7•]. A pre-planned follow-up study looked at combined radiographic data from PSUMMIT 1 and PSUMMIT 2 trials (total of 927 patients). The primary endpoint was the change in van der Heijde-Sharp (vdH-S) score from baseline to week 24. This analysis showed that both UST 45 and 90 mg lead to inhibition of radiographic progression of joint damage in PsA at 24 weeks. Follow-up to week 52 demonstrated maintained inhibition of radiographic progression for UST-treated patients, and substantial reduction of progression among initial placebo recipients who started UST at week 16 or week 24 [44•] . When looking at each trial alone, PSUMMIT 1 demonstrated significant radiographic progression, but a statistically significant reduction in x-ray progression was not seen in PSUMMIT 2 alone. This was thought to be related to the smaller sample size and numbers of missing radiographic data in a large proportion of the placebo patients [42] .
Safety of ustekinumab in treatment of psoriatic arthritis
A meta-analysis of the initial phase II and phase III trials of the anti-IL12/23 biologic agents (UST and briakinumab) in psoriasis raised concerns for major adverse cardiovascular events (MACEs) [45] . MACE is a composite endpoint of myocardial infarction, cerebrovascular accident, or cardiovascular death during the placebo-controlled phase of treatment in patients receiving at least one dose of study agent or placebo. Among 3179 subjects, ten MACEs were recorded in the placebo-control phase of these studies, compared with zero events in the placebo group of 1474 patients [45] , although the difference was not found to be statistically significant when the agents were looked at individually. Nevertheless, these findings lead to briakinumab eventually being pulled from clinical trials.
In spite of these initial concerns, a 5-year follow-up study of the patients in the PHOENIX 1, 2, and ACCEPT trials did not find a significant increase in the number of MACE events with UST vs. placebo. They looked at a total of 3117 patients followed for a period of 4-5 years-10,000 patient years. They recorded 40 MACE events in 37 patients, all of whom had at least two independent cardiovascular risk factors. Overall, the rates of stroke and cardiovascular death were 0.03/100 PY and 0.07/100 PY, not statistically significant compared with placebo. There was no dose-dependent difference in the rate of overall risk of adverse events in patients who received 45 vs. 90 mg of UST [46] . The rate of other adverse events, including infections and malignancy were not statistically significant for either dose. Therefore, the pooled long-term analysis of patients in the three phase III studies of UST in psoriasis did not show evidence of increased risk with dose or duration of therapy. Likewise, the PSUMMIT 1 and 2 trials showed no significant increased risk of infection or malignancy in patients treated with either dose of UST compared with placebo. No MACE events were observed through 16 weeks (the placebo-control phase) [7•, 8•] . Therefore, the information available to date shows that UST is not only efficacious but also safe in the treatment of PsA.
P19 component: a new target for blockade of IL23
As mentioned previously, IL12 and IL23 are heterodimeric cytokines with a common subunit (p40), which is targeted by UST. Studies in mice have demonstrated an increased IL23p19 subunit expression in psoriatic lesions, but no increase in the expression of the IL12p35 subunit [47] . These findings kindled interest in the concept that blockade of IL23 may be the more relevant target in psoriasis than IL12. Furthermore, IL23 has been shown to promote greater keratinocyte proliferation than IL12 [48] . In a phase I study, Nakajima et al. showed that treatment of mice with psoriatic plaques with anti-IL23p19 antibodies greatly inhibited epidermal hyperplasia [49] . Based on these results, new humanized IgG monoclonal antibodies (BI655066 [50] , guselkumab and tildrakizumab [51] formerly SCH900222 [52]), targeting the p19 subunit of IL23, were developed by several different companies and are currently in phase II clinical studies ( Table 2) .
The initial trials using these agents in psoriasis have proven promising [51, 53] . It remains to be seen whether these agents will be useful in the treatment of PsA as well as plaque psoriasis. Furthermore, the efficacy of IL23 blockade alone will need to be studied. All the studies with UST have benefited from the blockade of both IL12 and IL23. It is not known to what extent the blockade of IL12 is responsible for the clinical improvement seen in patients treated with UST.
IL17 blockade
While here, we have focused on IL12 and IL23 inhibition, several noteworthy drugs in the commercial pipelines for PsA focus on IL17 blockade. IL17 inhibitors including secukinumab [54] and ixekizumab [55, 56] , and the IL17 receptor [62] . Therefore, drugs that target IL17 and its receptor are an important part of the future armament against PsA.
IL22 blockade
As described earlier, Th17 cells secrete several pro-inflammatory cytokines that are important in the development of psoriasis. One of these cytokines is IL22, which is thought to cause hyperproliferation of keratinocytes, leading to the characteristic hyperkeratosis seen in PsA [63] . Serum IL22 levels have even been found to correlate with the disease severity of psoriasis patients [64] . Fezakinumab (formerly ILV-094) is a humanized monoclonal IgG antibody against IL-22, which progressed as far as phase II trials, but the data was not released [65] .
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